DUSP22 and metabolic dysfunction-associated steatohepatitis: These in vitro findings initially demonstrated the inhibitory effects of DUSP22 on lipid deposition, inflammation, and fibrosis, thus revealing that DUSP22 may possess therapeutic potential for NASH treatment.